^
    2ms
    LaserMucite: Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=97, Completed, Institut Cancerologie de l'Ouest | Unknown status --> Completed | Phase classification: P3 --> PN/A
    Trial completion • Phase classification
    2ms
    A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma. (PubMed, Funct Integr Genomics)
    Hypoxia upregulated the MSC-AS1/ITGA5 axis and increased VEGFA/PD-L1 expression, along with changes in the migrasome-related protein TSPAN4, suggesting a potential association with migrasome-related molecular features, which requires direct experimental validation. Collectively, our findings establish a novel MRL-based signature for prognostic prediction in HNSCC and highlight the hypoxia-responsive MSC-AS1/ITGA5 axis as a promising target for combinatorial therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ITGA5 (Integrin Subunit Alpha 5)
    |
    PD-L1 expression
    2ms
    Trilaciclib Combined With Immunochemotherapy for R/M HNSCC (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    Cosela (trilaciclib)
    2ms
    Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Stanford University | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    2ms
    A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, West China Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gilotrif (afatinib) • Tevimbra (tislelizumab-jsgr)
    2ms
    PYX-201-101: A Study of PYX-201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, Pyxis Oncology, Inc | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    micvotabart pelidotin (PYX-201)
    2ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=96 --> 210 | Trial completion date: Mar 2028 --> Mar 2029 | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • SHR-A2102 • AiRuiLi (adebrelimab)
    2ms
    Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) (clinicaltrials.gov)
    P2, N=36, Recruiting, Medical University of South Carolina | Initiation date: Jul 2026 --> Oct 2026
    Trial initiation date
    |
    NavDx®
    2ms
    Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P1, N=40, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab)
    2ms
    ORARAD: Observational Study of Dental Outcomes in Head and Neck Cancer Patients (clinicaltrials.gov)
    P=N/A, N=613, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    2ms
    PDGFRα+/Integrin α2+ Fibroblasts Orchestrate Tumor Budding in Oral Squamous Cell Carcinoma via Mechano-Metabolic Symbiosis: E-Cadherin/Integrin α2β1 Adhesion and Mitochondrial Transfer. (PubMed, Adv Sci (Weinh))
    Targeted inhibition of TNT-mediated mitochondrial transfer markedly suppresses TB in TBO and xenograft models. Together, our results reveal a mechano-metabolic symbiosis between PDGFRα+/integrin α2+ CAFs and OSCC cells that drives TB and provides actionable targets to block this aggressive metastatic precursor.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CDH1 (Cadherin 1) • PDGFA (Platelet Derived Growth Factor Subunit A)
    2ms
    MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Meiyouheng (becotatug vedotin)